← AbbVie Inc.

ABBV · Forward model · Bull case

The Bull case, 20 quarters out

Model as of

Each segment is projected from its own operating driver, rolled up into consolidated cash flow, and discounted back to a fair value per share. The assumptions below are editable — change them and every number on this page moves with them.

AbbVie operates as ONE reportable segment. The six verticals here are the revenue disaggregation AbbVie itself publishes - Immunology, Neuroscience, Oncology, Aesthetics, Other key products and the All other residual - and nothing finer is modelled, because nothing finer is disclosed. Five portfolio totals come from each quarter's own 8-K Exhibit 99.1 Key Product Revenues table; All other is the residual of consolidated revenue less those five, marked estimated on every point, and it reproduces the 10-Q All other line exactly at $1,109M for the basis quarter. The six verticals sum to the reported $16,990M of 2026 Q2 net revenues with no plug. No per-portfolio margin exists in any filing, so all six carry the same assumed 49.5% EBITDA margin - consolidated adjusted operating margin of 48.3% plus about 1.2 points of depreciation - and the 1.3% corporate overhead is the bridge from that basis-quarter print to the guided FY2026 adjusted operating margin approaching 47% of sales. Tax is the 14.5% adjusted rate the CFO forecast for the full year, applied unlevered: interest expense is not deducted from cash flow, because the $64.3B of net debt is deducted from enterprise value instead. Eye care disappeared from the disclosed tables in 2026 Q1 and was reclassified into All other with prior periods restated; that is a presentation change, not a divestiture. The Apogee acquisition announced 31 July 2026 is not in the base case at all - it had not closed at the basis quarter - and appears only as a named scenario.

ABBV forward model
Horizon
Fair value per share $354.02 +33% against $265.21
Terminal-year revenue $94.62B last four projected quarters
Enterprise value $689.85B $135.40B explicit + $554.45B terminal

The immunology duo keeps compounding and the drag shrinks. Skyrizi grew 24.4% and Rinvoq 24.5% in the basis quarter, and management raised the full-year Skyrizi number again to approximately $21.7 billion; Humira is now small enough that its decline stops mattering, and neuroscience is broadening as Vyalev more than doubles. This case adds growth across the board, a point of margin, a higher immunology terminal rate and a 17.5x exit. FY2030 revenue reaches $91.6B.

ABBV REVENUE MODEL

Latest: $25.04B (2031Q2E)

Period Value
2023Q3 $13.93B
2023Q4 $14.30B
2024Q1 $12.31B
2024Q2 $14.46B
2024Q3 $14.46B
2024Q4 $15.10B
2025Q1 $13.34B
2025Q2 $15.42B
2025Q3 $15.78B
2025Q4 $16.62B
2026Q1 $15.00B
2026Q2 $16.99B
2026Q3E $17.30B
2026Q4E $18.10B
2027Q1E $15.95B
2027Q2E $18.62B
2027Q3E $18.90B
2027Q4E $19.74B
2028Q1E $17.27B
2028Q2E $20.20B
2028Q3E $20.47B
2028Q4E $21.35B
2029Q1E $18.58B
2029Q2E $21.77B
2029Q3E $22.04B
2029Q4E $22.97B
2030Q1E $19.92B
2030Q2E $23.38B
2030Q3E $23.65B
2030Q4E $24.63B
2031Q1E $21.30B
2031Q2E $25.04B
Scenarios

Where each case comes from

Bear case — primary sources

The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Bear column is what happens if they are taken at face value.

Bull case — primary sources

The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Bull column is what happens if they are taken at face value.

Apogee case — primary sources

The primary sources this case is built from — filings, calls and posts. Where they are claims by an interested party rather than disclosures, every number in the Apogee column is what happens if they are taken at face value.

Valuation

From cash flow to fair value

The published model, discounted at 8.0% a year with an exit multiple of 17.5x on EBITDA. The horizon and sliders above do not change this walk.

Present value of free cash flow, 20 quarters$135.40B
Terminal-year revenue$94.62B
Terminal-year EBITDA$46.55B
Exit multiple, on EBITDA17.5x
Terminal value$814.66B
Discounted at 8.0% a year, terminal value becomes$554.45B
Share of enterprise value from the terminal80%
Enterprise value$689.85B
Net cash−$64.25B
Equity value$625.59B
Shares1.77B
Fair value per share$354.02
Against the deployed price of $265.21, as of +33%

Exit is taken on EBITDA at 16.0x, marginally below the 16.4x the market pays today on an enterprise value of $531.7B against about $32.4B of FY2026 adjusted EBITDA, so the base case re-rates nothing. The 7.9x revenue figure is the same enterprise value against the guided $67.6B and is carried only as a cross-check. The 8% discount rate is an assumed large-cap investment-grade pharma cost of capital; AbbVie discloses none.

Read the other way round: at $265.21 the market is paying 12.5x terminal-year EBITDA, holding every other assumption on this page fixed. That is the number to argue about.

Quarter by quarter

The projected path

The published model's 20 quarters. The horizon and sliders above do not change this table.

Quarter ImmunologyNeuroscienceOncologyAestheticsOther key productsAll other Revenue YoY EBITDA Capex FCF R40 PV of FCF
2026 Q3E $9.08B$3.35B$1.65B$1.18B$931M$1.10B $17.30B +10% $8.51B $311M $7.01B +50 $6.88B
2026 Q4E $9.75B$3.40B$1.66B$1.28B$927M$1.09B $18.10B +9% $8.91B $326M $7.34B +49 $7.06B
2027 Q1E $8.08B$3.06B$1.66B$1.14B$924M$1.08B $15.95B +6% $7.85B $287M $6.46B +47 $6.10B
2027 Q2E $10.26B$3.37B$1.67B$1.32B$921M$1.07B $18.62B +10% $9.16B $335M $7.54B +50 $6.99B
2027 Q3E $10.50B$3.52B$1.68B$1.22B$918M$1.07B $18.90B +9% $9.30B $340M $7.66B +50 $6.96B
2027 Q4E $11.18B$3.58B$1.69B$1.32B$916M$1.06B $19.74B +9% $9.71B $355M $8.00B +50 $7.13B
2028 Q1E $9.19B$3.23B$1.70B$1.18B$914M$1.05B $17.27B +8% $8.50B $311M $7.00B +49 $6.12B
2028 Q2E $11.59B$3.58B$1.71B$1.36B$912M$1.05B $20.20B +9% $9.94B $364M $8.19B +49 $7.02B
2028 Q3E $11.80B$3.74B$1.72B$1.26B$911M$1.04B $20.47B +8% $10.07B $368M $8.30B +49 $6.98B
2028 Q4E $12.50B$3.81B$1.73B$1.37B$909M$1.03B $21.35B +8% $10.50B $384M $8.65B +49 $7.14B
2029 Q1E $10.23B$3.45B$1.75B$1.23B$908M$1.03B $18.58B +8% $9.14B $334M $7.53B +48 $6.09B
2029 Q2E $12.85B$3.82B$1.76B$1.41B$907M$1.02B $21.77B +8% $10.71B $392M $8.82B +48 $7.01B
2029 Q3E $13.03B$4.00B$1.78B$1.31B$906M$1.01B $22.04B +8% $10.84B $397M $8.93B +48 $6.96B
2029 Q4E $13.76B$4.08B$1.79B$1.42B$906M$1.01B $22.97B +8% $11.30B $413M $9.31B +48 $7.11B
2030 Q1E $11.23B$3.70B$1.81B$1.27B$905M$1.00B $19.92B +7% $9.80B $359M $8.07B +48 $6.05B
2030 Q2E $14.08B$4.10B$1.83B$1.47B$905M$998M $23.38B +7% $11.50B $421M $9.47B +48 $6.96B
2030 Q3E $14.25B$4.29B$1.85B$1.36B$904M$993M $23.65B +7% $11.63B $426M $9.58B +48 $6.91B
2030 Q4E $15.02B$4.38B$1.86B$1.48B$904M$988M $24.63B +7% $12.12B $443M $9.98B +48 $7.06B
2031 Q1E $12.23B$3.97B$1.88B$1.33B$904M$982M $21.30B +7% $10.48B $383M $8.63B +47 $5.99B
2031 Q2E $15.31B$4.41B$1.90B$1.53B$903M$977M $25.04B +7% $12.32B $451M $10.15B +48 $6.91B

Every row is projected. A year-over-year change is shown only where the quarter it compares against exists — an em dash means there is no comparable quarter, not a flat year.

Track record

Model revisions

Assumptions are marked to reality as each quarter prints. Every change is appended here, with the fair value the model produced at the time, so the model's own history stays visible.

DateFair value thenNote
2026-08-27 $293.79 Model created from the verified 2026 Q2 research brief: twelve quarters of disclosed portfolio revenue, derived seasonality on immunology, neuroscience and aesthetics, and FY2026 calibrated against the guided approximately $67.6 billion.